Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/19822Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Drosos, A. A. | en |
| dc.contributor.author | van Vliet-Dascalopoulou, E. | en |
| dc.contributor.author | Andonopoulos, A. P. | en |
| dc.contributor.author | Galanopoulou, V. | en |
| dc.contributor.author | Skopouli, F. N. | en |
| dc.contributor.author | Moutsopoulos, H. M. | en |
| dc.date.accessioned | 2015-11-24T19:02:38Z | - |
| dc.date.available | 2015-11-24T19:02:38Z | - |
| dc.identifier.issn | 0392-856X | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19822 | - |
| dc.rights | Default Licence | - |
| dc.subject | Double-Blind Method | en |
| dc.subject | Hirsutism/chemically induced | en |
| dc.subject | Hoarseness/chemically induced | en |
| dc.subject | Humans | en |
| dc.subject | Libido/drug effects | en |
| dc.subject | Lymphocytes/pathology | en |
| dc.subject | Middle Aged | en |
| dc.subject | Nandrolone/adverse effects/*analogs & derivatives/therapeutic use | en |
| dc.subject | Pilot Projects | en |
| dc.subject | Salivary Glands/pathology | en |
| dc.subject | Sjogren's Syndrome/*drug therapy/pathology | en |
| dc.title | Nandrolone decanoate (deca-durabolin) in primary Sjogren's syndrome: a double blind pilot study | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/3396249 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1988 | - |
| heal.abstract | The efficacy and side-effects of Deca-Durabolin (DD) were tested, in a double blind fashion, in twenty female primary Sjogren's syndrome (1 degree SS) patients. Ten randomly assigned patients received DD (100 mg IM bi-weekly) for six months, and ten others placebo, for the same period. Analysis of the results revealed that the DD-treated patients showed a moderate improvement of subjective xerostomia, a significant decrease of the erythrocyte sedimentation rate (ESR), and an overall improvement of their feeling of well-being, -judged by themselves and the investigator subjectively-, when compared with the placebo group. All the sicca objective parameters (results of Schirmer's I test, slit lamp eye examination after rose bengal staining, stimulated parotid flow rate measurements and labial minor salivary gland histopathology) were not significantly altered in either group. The clinical side-effects were the expected ones, i.e. hirsutism, hoarseness and an increase in libido, more pronounced in the DD-treated group. At the end of the study, one DD-treated patient, developed a diffuse well-differentiated B-lymphocytic lymphoma, which regressed spontaneously three months later. | en |
| heal.journalName | Clin Exp Rheumatol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
